Ferraldeschi et al. [42] showed that PTEN loss contributes to resistance to androgen deprivation therapies and newer treatments for castration-resistant PCa, such as enzalutamide and abiraterone. The gene discussed is PTEN; the disease is posterior cortical atrophy.